P Francioli

16.0k citations

195 papers · 10.1k indexed · 3 hit papers · h-index 51

Infectious Diseases top 0.1%
Epidemiology top 0.5%
Virology top 0.2%
Public Health, Environmental and Occupational Health top 1%
Molecular Biology top 10%

Co-authors: Dominique Blanc Amalio Telenti Jacques Billé Markus Flepp M. P. Glauser Philippe Sudre Bernard Hirschel Hansjakob Furrer
Topics: Antimicrobial Resistance in Staphylococcus (46 papers)Infective Endocarditis Diagnosis and Management (40 papers)Streptococcal Infections and Treatments (27 papers)
Cited by: Virology Infectious Diseases Clinical Biochemistry
Journals: The Lancet JAMA Circulation
Partner nations: Switzerland France United States

In The Last Decade

P Francioli

188 papers receiving 9.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1999 772 citations Bruno Ledergerber, Amalio Telenti et al. profile →
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

2000 692 citations Gilbert Greub, Hansjakob Furrer et al. profile →
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study

1997 502 citations Bernard Hirschel, P Francioli et al. profile →

Peers

Countries citing papers authored by P Francioli

Since Specialization

Citations

This map shows the geographic impact of P Francioli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Francioli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Francioli more than expected).

Fields of papers citing papers by P Francioli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Francioli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Francioli. The network helps show where P Francioli may publish in the future.

Co-authorship network of co-authors of P Francioli

This figure shows the co-authorship network connecting the top 25 collaborators of P Francioli. A scholar is included among the top collaborators of P Francioli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Francioli. P Francioli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of standardised review of intravenous antibiotic therapy 72 hours after prescription in two internal medicine wards 2009 ·Journal of Hospital Infection ·Oriol Manuel,Bernard Burnand,Pierre Bady,(unknown),(unknown),P Francioli,Gláucia Zanetti	22
2	Borréliose de Lyme 1ère partie: épidémiologie et diagnostic 2006 ·Revue Médicale Suisse ·Rainer Weber,(unknown),Christoph Aebi,Stefan Zimmerli,P Francioli,Olivier Péter,Stefano Bassetti	2
3	Borréliose de Lyme 2e partie: clinique et traitement 2006 ·Revue Médicale Suisse ·Rainer Weber,(unknown),Christoph Aebi,Stefan Zimmerli,P Francioli,Olivier Péter,Stefano Bassetti	3
4	Borréliose de Lyme - 3ème partie : Prévention, grossesse, états d'immunodéficience, syndrome post-borréliose de Lyme 2006 ·Archive ouverte UNIGE (University of Geneva) ·(unknown),Christoph Aebi,P Francioli,O Péter,Stefano Bassetti,Alain Gervaix,(unknown),(unknown)	0
5	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 1: Epidemiologie und Diagnostik 2005 ·Schweizerische Ärztezeitung ·(unknown),Christoph Aebi,P Francioli,O Péter,(unknown),Alain Gervaix,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	2
6	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 3: Prävention, Schwangerschaft, Immundefizienz, Post-Lyme-Syndrom 2005 ·Schweizerische Ärztezeitung ·(unknown),Christoph Aebi,P Francioli,O Péter,(unknown),Alain Gervaix,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	3
7	Abklärung und Therapie der Lyme-Borreliose bei Erwachsenen und Kindern: Empfehlungen der Schweizerischen Gesellschaft für Infektiologie. Teil 2: Klinik und Therapie 2005 ·Schweizerische Ärztezeitung ·(unknown),Christoph Aebi,P Francioli,O Péter,(unknown),Alain Gervaix,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	7
8	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy 2002 ·AIDS ·Gilbert Greub,Alessandro Cozzi‐Lepri,Bruno Ledergerber,Schlomo Staszewski,Luc Perrin,Veronica Miller,P Francioli,Hansjakob Furrer,Manuel Battegay,Pietro Vernazza,Enos Bernasconi,Huldrych F. Günthard,Bernard Hirschel,Andrew Phillips,Amalio Telenti	95
9	Der aktuelle Stand der Grippeprävention 2001 ·Schweizerische Ärztezeitung ·(unknown),Dominique Blanc,André P. Burnens,P Francioli,Christoph Hatz,Kathrin Mühlemann,Didier Pittet,(unknown),Robert Steffen,Nicolas Troillet,Rainer Weber,Andreas F. Widmer,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	1
10	Extreme Ops (Film) 2001 ·Sight & sound/Sight and sound ·Nicolas Troillet,Christiane Pétignat,Maurice Matter,Marie‐Christine Eisenring,(unknown),P Francioli	6
11	Prévention des infections à pneumocoques par la vaccination 2000 ·Schweizerische Ärztezeitung ·Kathrin Mühlemann,Dominique Blanc,A Burnens,P Francioli,Daniel Germann,Christoph Hatz,Didier Pittet,(unknown),Robert Steffen,Nicolas Troillet,Rainer Weber,Andreas F. Widmer,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown)	0
12	Viral toad changes in response to antiretroviral therapy according to the baseline CD4 lymphocyte count and viral load 2000 ·UCL Discovery (University College London) ·AN Phillips,S Staszewski,Rainer Weber,Ole Kirk,P Francioli,Miller,Pietro Vernazza,Jens Lundgren,Bruno Ledergerber	3
13	III. Typing methods to approachPneumocystis cariniigenetic heterogeneity 1998 ·FEMS Immunology & Medical Microbiology ·Philippe M. Hauser,Dominique Blanc,Jacques Billé,P Francioli	25
14	The Impact of Penicillinase on Cefamandole Treatment and Prophylaxis of Experimental Endocarditis Due to Methicillin‐ResistantStaphylococcus aureus 1998 ·The Journal of Infectious Diseases ·Yok‐Ai Que,(unknown),P Francioli,Philippe Moreillon	23
15	Frequency and molecular diversity of Pseudomonas aeruginosa upon admission and during hospitalization: a prospective epidemiologic study 1998 ·Clinical Microbiology and Infection ·Dominique Blanc,Christiane Pétignat,(unknown),Jacques Billé,P Francioli	70
16	Molecular typing methods and their discriminatory power 1998 ·Clinical Microbiology and Infection ·Dominique Blanc,Philippe M. Hauser,P Francioli,Jacques Billé	15
17	Evolution du spectre des infections opportunistes de 1988 à 1994 : Expérience de l'Etude Suisse de Cohorte VIH (SHCS) 1996 ·IRIS ·(unknown),(unknown),(unknown),P Francioli	1
18	[Epidemiology of pneumonias diagnosed in an ambulatory practice]. 1992 ·PubMed ·P Francioli,Franklin G. Moser	1
19	[364 anonymous screening tests for AIDS at the Vaudois University Hospital Center: who? why?]. 1990 ·PubMed ·(unknown),(unknown),(unknown),P Francioli	1
20	Hémobilie et syndrome de Chiari posttraumatiques. 1954 ·P Francioli,(unknown),F Saegesser	1

About P Francioli

P Francioli is a scholar working on Infectious Diseases, Clinical Biochemistry and Virology, having authored 195 papers that have together received 10.1k indexed citations. Recurring topics across this work include Antimicrobial Resistance in Staphylococcus (46 papers), Infective Endocarditis Diagnosis and Management (40 papers) and Streptococcal Infections and Treatments (27 papers). The work is most often cited by research in Virology (2.0k citations), Infectious Diseases (6.1k citations) and Clinical Biochemistry (1.0k citations). P Francioli has collaborated with scholars based in Switzerland, France and United States. Frequent co-authors include Dominique Blanc, Amalio Telenti, Jacques Billé, Markus Flepp, M. P. Glauser, Philippe Sudre, Bernard Hirschel, Hansjakob Furrer, Pietro Vernazza and Matthias Egger. Their work appears in journals such as The Lancet, JAMA and Circulation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact